{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.1","upperLimit":"16.1","value":"8.1"},{"groupId":"OG001","lowerLimit":"7.9","upperLimit":"17.6","value":"15.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"description":"PFS is defined as the time from the first dose of study medication to the earliest of death or progression (at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 millimeters (mm). If a participant received subsequent anti-cancer therapy prior to the date of documented PD/death, the participant was censored at the last adequate assessment and the visit level response was CR (disappearance of all target lesions), PR (at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters \\[e.g., percent change from Baseline\\]), or stable disease (SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants who received no prior local therapy for brain metastasis received GSK2118436 150 mg capsules either one hour before or 2 hours after a meal twice daily until evidence of disease progression, death, or unacceptable adverse events.","id":"OG000","title":"GSK2118436 150 mg: No Prior Local Therapy"},{"description":"Participants who received prior local therapy for brain metastasis received GSK2118436 150 mg capsules either one hour before or 2 hours after a meal twice daily until evidence of disease progression, death, or unacceptable adverse events.","id":"OG001","title":"GSK2118436 150 mg: Prior Local Therapy"}],"paramType":"MEDIAN","populationDescription":"V600K Population","reportingStatus":"POSTED","timeFrame":"Time from the first dose of study medication to the earliest of death or progression (average of 17 weeks)","title":"Progression-free Survival in V600K Mutation-positive Participants","type":"SECONDARY","unitOfMeasure":"weeks"}